Maraver’s lab recapitulated this acquired molecular resistance mechanism by generating an EGFR/MET transgenic mouse model and showed the addition of MET inhibitors to osimertinib-induced tumor regression [156]. The gene discussed is EGFR; the disease is neoplasm.